Trial | NCT00421018  Report issue

Title

Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    montelukast ...

  • Study Participants

    187
The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma
Study Started
Nov 30
2006
Primary Completion
Apr 30
2010
Study Completion
Apr 30
2010
Last Update
Aug 15
2012
Estimate

Drug Single corticosteroid inhalers and Singulair

Treatment steps according to preset algorithm

Symptom-guided group Sham Comparator

Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.

FeNO-guided group Active Comparator

Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide

Criteria 

Inclusion Criteria:

Age 18-64
Clinical diagnosis of Asthma
Glucocorticoid treatment > 6 months.
Verified Allergy
Read and speak Swedish

Exclusion Criteria:

Smoking
Current regular treatment with long-acting beta2-agonist
Treatment with Singulair only or in combination with glucocorticoids
Taking part in other research study
Pregnancy or breast-feeding
Unstable Asthma
No Results Posted